Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus

Scandinavian Journal of Immunology

Volumn 57, Issue 6, 2003, Pages 568-572

  Liu, M F ^a,b   Wang, C R ^a   Chen, P C ^a   Fung, L L ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PATIENT; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; BASE SEQUENCE; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOCONJUGATES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SOLUBILITY;

EID: 0038040546     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01232.x     Document Type: Article

References (12)

1. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-58.
2. Harper K, Balzano C, Rouvier E, Matti MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991;147:1037-44.
3. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
4. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-50.
5. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996;184:783-8.
6. Magistrelli G, Jeannin P, Herbault N et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29:3596-602.
7. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tecror AJ. A native soluble form of CTLA-4. Cell Immunol 2000;201:144-53.
8. Liu MF, Liu HS, Wang CR, Lei HY. Expression of CTLA-4 molecule in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. J Clin Immunol 1998;18:392-8.
9. Deichmann K, Heinzmann A, Bruggenolte E et al. A Mse I RFLP in the human CTLA-4 promoter. Biochem Biophys Res Commun 1996;225:817-8.
10. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Bombardier C, Gladman DD, Urowitz MB et al. Comitree on prognosis studies in SLE. Derivation of the SLEDAI. Arthritis Rheum 1992;35:630-40.
12. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-8.